OneSource Specialty Pharma Limited announced the amalgamation of its wholly-owned subsidiaries, Stelis Pte. Limited and OneSource Specialty Pte. Limited. Effective January 1, 2026, this strategic move aims to simplify the corporate structure, enhance operational efficiency, and reduce administrative costs. The combined turnover of the entities for the fiscal year ending March 31, 2025, was approximately USD 41.95 million.
Subsidiary Amalgamation Details
OneSource Specialty Pharma Limited has completed the amalgamation of its two wholly-owned subsidiaries, Stelis Pte. Limited and OneSource Specialty Pte. Limited. This consolidation took effect on January 1, 2026.
Rationale Behind the Amalgamation
The primary goal of this amalgamation is to streamline the existing corporate hierarchy. By consolidating these entities, OneSource Specialty Pharma aims to improve its operational efficiency. In addition to streamlined operations, the amalgamation seeks to reduce redundant administrative, compliance, and legal costs.
Financial Overview of the Entities
The combined turnover of Stelis Pte. Limited and OneSource Specialty Pte. Limited for the financial year ended March 31, 2025, was USD 41.95 million. Stelis Pte. Limited recorded a turnover of USD 7.86 million, while OneSource Specialty Pte. Limited had a turnover of USD 34.09 million.
Impact on Shareholding
As this amalgamation involves only wholly-owned subsidiaries, the shareholding pattern of OneSource Specialty Pharma Limited remains unchanged. The shares of Stelis Pte. Limited held by the Company will be cancelled, and OneSource Specialty Pte. will issue shares to the Company.
Business Focus
The amalgamation brings together Stelis’s manufacturing of pharmaceutical products with OneSource Specialty Pte.’s focus on developing, marketing, and distributing pharmaceutical goods. Stelis is primarily involved in the manufacturing of pharmaceutical products and preparations for human use. OneSource Specialty Pte. is focused on developing, marketing, and distributing pharmaceutical goods, including injectables.
Source: BSE
